Drug intelligence / Profile preview

CD33 CAR CIK + TIM-3 CCR CIK

Development stage: Preclinical
Lead developer: University of Milano-Bicocca
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CD33 CAR CIK + TIM-3 CCR CIK is a dual-targeting cell therapy developed for the treatment of Acute Myeloid Leukemia (AML). It utilizes Cytokine-Induced Killer (CIK) cells engineered via the Sleeping Beauty transposon system to express two distinct components: a second-generation Chimeric Antigen Receptor (CAR) targeting CD33 and a Chimeric Costimulatory Receptor (CCR) targeting TIM-3 (T-cell Immunoglobulin Mucin-3). This "IF-BETTER" logic gating strategy is designed to enhance therapeutic precision by leveraging the broad expression of CD33 on AML blasts and the selective enrichment of TIM-3 on leukemic stem cells (LSCs). The TIM-3 binding domain is a glycosylation-tolerant scFv (derived from clone M6903) that preferentially recognizes hyper-fucosylated and hyper-sialylated TIM-3 glycoforms unique to AML cells, thereby sparing healthy hematopoietic stem cells and immune cells that express different TIM-3 glycoforms.

Other names: CD33.CAR/TIM-3.CCR CIKIF-BETTER CD33/TIM-3 dual CAR-CIK

Targets

HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on CD33 CAR CIK + TIM-3 CCR CIK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD33 CAR CIK + TIM-3 CCR CIK.

Explore the full profile